Ethic Inc. Buys 1,148 Shares of Medpace Holdings, Inc. $MEDP

Ethic Inc. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 36.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,275 shares of the company’s stock after acquiring an additional 1,148 shares during the quarter. Ethic Inc.’s holdings in Medpace were worth $2,198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. State of Wyoming raised its holdings in Medpace by 24.6% during the 1st quarter. State of Wyoming now owns 365 shares of the company’s stock worth $111,000 after purchasing an additional 72 shares during the last quarter. Royal Bank of Canada increased its position in shares of Medpace by 0.7% during the first quarter. Royal Bank of Canada now owns 48,732 shares of the company’s stock worth $14,849,000 after buying an additional 334 shares during the period. Focus Partners Advisor Solutions LLC raised its stake in Medpace by 55.8% during the first quarter. Focus Partners Advisor Solutions LLC now owns 1,097 shares of the company’s stock worth $334,000 after buying an additional 393 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Medpace by 12.4% in the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock valued at $158,470,000 after buying an additional 59,361 shares during the period. Finally, Hancock Whitney Corp lifted its holdings in Medpace by 3.9% in the first quarter. Hancock Whitney Corp now owns 50,206 shares of the company’s stock valued at $15,297,000 after buying an additional 1,902 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 387,925 shares of company stock worth $233,386,647 in the last quarter. Insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. TD Cowen lifted their target price on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a report on Friday, October 24th. Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $490.82.

Medpace Stock Down 1.3%

Shares of MEDP opened at $561.65 on Thursday. The business’s fifty day moving average is $580.89 and its 200 day moving average is $486.96. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The stock has a market cap of $15.82 billion, a P/E ratio of 39.28, a P/E/G ratio of 2.15 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the prior year, the company posted $3.01 earnings per share. The business’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.